Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,130.00
(
0.48%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
99.36
(
-1.29%
)
Bitcoin
74,535.16
(
0.80%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 136181

Tuesday, 05/01/2012 4:35:05 PM

Tuesday, May 01, 2012 4:35:05 PM

Post# of 257253
1Q12 US Tysabri sales were $201M, +18% YoY; half of the 18% increase was attributable to volume and half was attributable to price increases:

http://pharma411.visibli.com/share/ftNWk7
http://seekingalpha.com/article/547121-biogen-idec-s-ceo-discusses-q1-2012-results-earnings-call-transcript

Relative to 4Q11, US Tysabri sales increased 2.5%.

p.s. BIIB deserves credit for disclosing the change in unit volume as well as dollar sales; more biotech companies ought to do that.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now